Lantern Pharma (NASDAQ: LTRN) announced it will host its first live, public demonstration of its withZeta.ai multi-agentic AI co-scientist platform on April 30, 2026, with two sessions scheduled to accommodate global audiences. The event will feature a real-time, interactive demonstration led by CEO Panna Sharma, showcasing the platform's ability to execute complex oncology research workflows by integrating clinical, molecular and scientific datasets. Lantern said the platform is designed to accelerate drug discovery timelines, particularly in rare cancers, while supporting a scalable, subscription-based commercial model.
This demonstration represents a significant milestone for Lantern Pharma as it transitions from developing AI tools internally to offering them as a commercial product. The withZeta.ai platform is now available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the company. By providing a multi-agentic AI co-scientist, Lantern aims to reduce the time and cost associated with traditional drug discovery, especially in areas where treatment options are limited.
Lantern Pharma is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR platform to transform the development of cancer therapies. Its clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary.
The ability to perform real-time interactive demonstrations of complex AI workflows could attract pharmaceutical companies and research institutions seeking to expedite their own drug development programs. The platform's integration of clinical, molecular, and scientific datasets enables researchers to generate insights that might otherwise take years to uncover. As Lantern Pharma continues to expand its AI capabilities, the company operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.
Investors and industry watchers will be closely monitoring the demonstration to assess the platform's potential impact on Lantern's revenue and its broader implications for AI in oncology. The full press release is available at https://ibn.fm/wzevl. For more information about Lantern Pharma, visit the company's newsroom at https://ibn.fm/LTRN.
